Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer
Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer
Local treatment in addition to endocrine treatment as 1st line for oligo-metastatic
 ER-positive/HER2-negative breast cancer.
Local treatment included surgical resection, stereotactic body radiotherapy, palliative
 radiotherapy, and radiofrequency ablation. Stereotactic body radiotherapy is preferred as a
 radiation modality.

 Endocrine therapies with/without target therapy including CDK4/6 inhibitors or mTOR
 inhibitors are the mainstay of 1st line treatment for ER-positive/HER2-negative metastatic
 breast cancer.
Inclusion Criteria:

 -ER-positive/HER2-negative in primary tumor

 -  Oligometastases: ≤ 2 lesions in single organ or site (lung, bone, liver, adrenal
 glands, distant LNs)

 -  Recurrent cancer after completion of primary treatment (RFI≥1year)

 -  Metastatic lesions are feasible for resection or radiotherapy (Size≤3cm)

 Exclusion Criteria:

 -  De Novo metastatic cancer at initial diganosis

 -  Recurrence-free inverval < 1 year